Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Breast cancer

NICE recommends two new breast cancer drugs

Thousands of British women with breast cancer will have access to two new drugs after the UK’s National Institute for Health and Care Excellence (NICE) recommended them for routine funding.

The two drugs, palbociclib, manufactured by Pfizer, and ribociclib, from Novartis, are recommended for patients with oestrogen-receptor positive, HER2-negative advanced or secondary breast cancer. The drugs have been shown to slow the growth of cancer for an average of ten months. 

NICE provides guidance, advice and quality standards to the NHS, including technology appraisals guidance on the cost-effectiveness of health technologies.

The agency had previously rejected palbociclib as too expensive in relation to its clinical effectiveness. 

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said its new decision came after drug manufacturers provided more evidence for their effectiveness and negotiated a lower price with health officials.

“The committee heard that by postponing disease progression, palbociclib and ribociclib may reduce the number of people who are exposed to the often unpleasant side effects of chemotherapy, and delay the need for its use in others,” she said.

“We are pleased, therefore, that the companies have been able to agree reductions to the price of palbociclib and ribociclib to allow them to be made routinely available to people with this type of breast cancer.” 

There are approximately 45,000 new diagnoses of breast cancer annually in England, and an estimated 8,000 of these would be eligible for treatment with either of the two drugs. 

Palbociclib is given to eligible patients who were diagnosed with cancer after it had already spread to other parts of the body; eligible women who have gone through the menopause can be given ribociclib.

Nicholas Turner, professor of molecular oncology at the Institute of Cancer Research, which led the major clinical trial into palbociclib with the Royal Marsden NHS Foundation Trust, welcomed NICE’s decision. 

“The development of this brand of new class of cancer drug is one of the most important breakthroughs for women with advanced breast cancer in the last two decades,” he said, adding, “These drugs have allowed women to live a normal life for longer.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20204005

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • nice-office-logo-15

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.